Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy

A Phase I study was performed to determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic profile of irinotecan (CPT-11) and its active metabolites when given on a once-every-3-week schedule. Thirty-four patients with advanced refractory solid malignancies were treated with CPT-11...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2000-06, Vol.6 (6), p.2236
Hauptverfasser:	Pitot, H C, Goldberg, R M, Reid, J M, Sloan, J A, Skaff, P A, Erlichman, C, Rubin, J, Burch, P A, Adjei, A A, Alberts, S A, Schaaf, L J, Elfring, G, Miller, L L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Anesthesia - pharmacology Adult Aged Aged, 80 and over Antidiarrheals - pharmacology Antiemetics - pharmacology Antineoplastic Agents, Phytogenic - blood Antineoplastic Agents, Phytogenic - pharmacokinetics Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Agents, Phytogenic - toxicity Area Under Curve Atropine - pharmacology Camptothecin - analogs & derivatives Camptothecin - blood Camptothecin - pharmacokinetics Camptothecin - therapeutic use Camptothecin - toxicity Colorectal Neoplasms - drug therapy Dexamethasone - pharmacology Digestive System - drug effects Dose-Response Relationship, Drug Esophageal Neoplasms - drug therapy Female Follow-Up Studies Gallbladder Neoplasms - drug therapy Glucuronates - blood Glucuronates - pharmacokinetics Humans Loperamide - pharmacology Male Maximum Tolerated Dose Middle Aged Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!